|Title:||Taiwan consensus of pharmacological treatment for bipolar disorder||Authors:||Bai, Ya-Mei
Shen, Winston W.
|Keywords:||bipolar disorder;consensus;pharmacotherapy;Taiwan||Issue Date:||2013||Start page/Pages:||547-556||Source:||Journal of the Chinese Medical Association||Abstract:||
Bipolar disorder is an important psychiatric disorder with different disease phases. The pharmacological treatment is complicated, and is updated frequently as new research evidence emerges. For the purpose of international collaboration, research, and education, the Taiwan consensus of pharmacological treatment for bipolar disorders was initiated by the Taiwanese Society of Biological Psychiatry and Neuropsychopharmacology (TSBPN) - the Bipolar Chapter, which was established in August 2010 and approved as a member of International Society of Bipolar Disorder. TSBPN is the country member of the World Federation of Societies of Biological Psychiatry (WFSBP). The development of the Taiwan consensus for bipolar disorder was mainly based on the template of WFSBP Guidelines, with references to other international guidelines including the Canadian Network for Mood and Anxiety Treatments, and British Association for Psychopharmacology. We have also added Taiwanese experts' experience, Taiwan national health insurance data, and the indications for the pharmacological treatment of bipolar disorder given by the Taiwan Department of Health, to emphasize the balance between efficacy and safety, and to make this consensus a concise, empirical, and important reference for clinical psychiatric practice. Copyright (C) 2013 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
amisulpride; aripiprazole; carbamazepine; chlorpromazine; clotiapine; clozapine; flupentixol; fluphenazine; haloperidol; lamotrigine; lithium; loxapine; olanzapine; oxcarbazepine; paliperidone; quetiapine; risperidone; sulpiride; thioridazine; trifluoperazine; valproic acid; ziprasidone; zotepine; agranulocytosis; bipolar depression; bipolar disorder; consensus; drug efficacy; drug safety; electroconvulsive therapy; extrapyramidal symptom; genotype; human; mania; metabolic syndrome X; national health insurance; nerve stimulation; neuropharmacology; practice guideline; rash; review; sedation; side effect; Stevens Johnson syndrome; Taiwan; toxic epidermal necrolysis; weight gain; bipolar disorder; consensus; pharmacotherapy; Taiwan; Bipolar Disorder; Consensus; Humans; Randomized Controlled Trials as Topic; Taiwan
|Appears in Collections:||醫學系|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.